Fly News Breaks for February 20, 2020
Feb 20, 2020 | 06:57 EDT
Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Reata Pharmaceuticals to $320 from $314 and reiterates an Overweight rating on the shares following the company's Q4 results.
News For RETA From the Last 2 Days
There are no results for your query RETA